Suppr超能文献

抗甲状腺药物治疗后的肝毒性和皮肤反应。

Hepatotoxicity and cutaneous reactions after antithyroid drug administration.

机构信息

Ito Hospital, Tokyo, Japan.

出版信息

Clin Endocrinol (Oxf). 2012 Aug;77(2):310-5. doi: 10.1111/j.1365-2265.2012.04365.x.

Abstract

OBJECTIVE

Use of the antithyroid drugs (ATDs) thiamazole (MMI) and propylthiouracil (PTU) is associated with a high frequency of side effects. When patients experience side effects with one (the 1st) ATD, it is usually discontinued and another is administered (the 2nd ATD). We investigated side effects associated with the 1st and 2nd ATDs.

DESIGN AND PATIENTS

Four hundred forty-nine patients with untreated Graves' disease (GD) were randomly assigned to three groups according to ATD type and/or dosage: 15 mg/day MMI, 30 mg/day MMI and 300 mg/day PTU. The type, frequency and onset of side effects were assessed. We also studied the side effects associated with the 2nd ATD after cessation of the 1st ATD.

MEASUREMENTS

Cutaneous reactions, liver dysfunction and other side effects were examined every 2 weeks after starting ATD administration.

RESULTS

The overall frequency of side effects in patients taking 15 mg/day MMI was low. The frequencies of cutaneous reactions in patients taking 30 mg/day MMI and hepatotoxicity in those taking 300 mg/day PTU were high. Hepatotoxicity developed later than cutaneous reactions with PTU. Hepatotoxicity developed earlier in the 30 mg/day MMI group than in the other two groups. The frequency of side effects did not differ between the 2nd and 1st ATDs. Hepatotoxicity occurred at a higher frequency in patients who were switched from MMI to PTU because of hepatotoxicity of the former.

CONCLUSION

Attention to the onset times of side effects and cross-reactivity of ATDs can lead to safer treatment of GD.

摘要

目的

使用抗甲状腺药物(ATD)甲巯咪唑(MMI)和丙基硫氧嘧啶(PTU)与高频率的副作用相关。当患者出现一种(第 1 种)ATD 的副作用时,通常会停用该药物并改用另一种(第 2 种)ATD。我们调查了与第 1 种和第 2 种 ATD 相关的副作用。

设计和患者

449 例未经治疗的 Graves 病(GD)患者根据 ATD 类型和/或剂量随机分为三组:每天 15 毫克 MMI、每天 30 毫克 MMI 和每天 300 毫克 PTU。评估了副作用的类型、频率和发生时间。我们还研究了停用第 1 种 ATD 后第 2 种 ATD 相关的副作用。

测量

在开始使用 ATD 治疗后每 2 周检查皮肤反应、肝功能障碍和其他副作用。

结果

服用 15 毫克/天 MMI 的患者总体副作用发生率较低。服用 30 毫克/天 MMI 的患者皮肤反应发生率高,服用 300 毫克/天 PTU 的患者肝毒性发生率高。PTU 引起的肝毒性比皮肤反应晚。30 毫克/天 MMI 组比其他两组更早发生肝毒性。第 2 种和第 1 种 ATD 的副作用发生率没有差异。因前者的肝毒性而改用 PTU 的患者肝毒性发生率更高。

结论

注意副作用的发生时间和 ATD 的交叉反应可以使 GD 的治疗更安全。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验